Deregulated Polycomb functions in myeloproliferative neoplasms
نویسندگان
چکیده
منابع مشابه
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.
The polycomb repressive complex 2 (PRC2) is a highly conserved histone H3 lysine 27 methyltransferase that regulates the expression of developmental genes. Inactivating mutations of the catalytic component of PRC2, EZH2, are seen in myeloid disorders. We reasoned that the other 2 core PRC2 components, SUZ12 and EED, may also be mutational targets in these diseases, as well as associated factors...
متن کاملEpigenetics in Myeloproliferative Neoplasms
A decade on from the description of JAK2 V617F, the MPNs are circumscribed by an increasingly intricate landscape. There is now evidence that they are likely the result of combined genetic dysregulation, with several mutated genes involved in the regulation of epigenetic mechanisms. Epigenetic changes are not due to a change in the DNA sequence but are reversible modifications that dictate the ...
متن کاملMutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms
Alterations of epigenetic marks have an important role in myeloid malignancies. Mutations have been found in several epigenetic regulators including ASXL1, DNMT3A, EZH2, IDH1/2 and TET2. DNMT3A, IDH1/2 and TET2 are involved in the regulation of DNA methylation. EZH2 belongs to a complex of proteins called ‘polycomb repressor complex 2’ (PRC2). ASXL1 is a regulator of PRC1, the other polycomb co...
متن کاملEsophageal lesions in myeloproliferative neoplasms.
A 67-year-old man was admitted to our hospital with worsening odynophagia. He had been diagnosed as having chronic neutrophilic leukemia based on excessive neutrophilia without blasts, anemia, hyperplastic bonemarrowwith normal neutrophilic maturation, and hepatosplenomegaly, without bcr/abl rearrangement [1]. Finally, he was rediagnosed as having myeloproliferative neoplasm (MPN), unclassifiab...
متن کاملMyeloproliferative neoplasms and thrombosis.
Major causes of morbidity and mortality in myeloproliferative neoplasms are represented by arterial and venous complications, progression to myelofibrosis, and transformation to acute leukemia. The pathogenesis of thrombosis results from a complex interplay of clinical and disease-related factors. Abnormalities of blood cells arising from the clonal proliferation of hematopoietic stem cells inv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Hematology
سال: 2019
ISSN: 0925-5710,1865-3774
DOI: 10.1007/s12185-019-02600-6